Navigation Links
D-Pharm Secures Funding From Israel's Chief Scientist's Office
Date:4/6/2008

REHOVOT, Israel, April 7 /PRNewswire/ -- D-Pharm announced today that it received notice from Israel's Chief Scientist's Office (CSO) of its commitment to match expenditures on four of D-Pharm's R&D programs with a total grant of up to NIS 11 million (over $3 million).

Alex Kozak, PhD, CEO and President of D-Pharm, said "We are grateful to the CSO for this vote of confidence and its firm support over the years, from the time of the company's inception as a technological incubator. The CSO's backing has helped us to build a robust pipeline with two advanced clinical stage products in stroke (DP-b99) and epilepsy and migraine (DP-VPA) followed by an exciting range of preclinical developments in Alzheimer's disease, cancer and psoriasis".

D-Pharm's drug-development programs emerged from the company's unique platform technology of lipid-like medicine. The CSO grant supports four major company developments: GMP production of DP-b99 in-house, IND preparations and initiation of a pivotal Phase III trial in stroke patients; a Phase II migraine study of DP-VPA in Israeli medical centers; and two preclinical programs, DP-460 for Alzheimer's disease and LipidoMimetix for cancer.

The Chief Scientist's Office has supported D-Pharm since its establishment, providing grants of about $18 million, excluding this latest announcement.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. D-Pharm recently received Israeli health ministry approval to commence a Phase II study of DP-VPA in migraine patients. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer. D-Pharm recently completed a $5 million rights issue to ensure timely commencement of the pivotal Phase III study of DP-b99, in acute stroke patients, as planned.

For further information please contact:

Tami Horovitz, PhD.

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com


'/>"/>
SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. Aerovance Secures $20 Million in Debt Financing
3. Amarin Secures Global Intellectual Property Rights for Lipid Programs
4. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
5. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
6. Taligen Therapeutics Secures Series B Financing
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Dendreon Secures $130 Million Committed Equity Financing Facility
9. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Coral Springs, FL (PRWEB) , ... August 17, ... ... today announced that the stock market news outlet had provided a research update ... the company's nasally administered TRT product. , According to Soulstring, prescription rates for ...
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... by changing into a different cell type. Many treatments for specific cancers, such ... prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
(Date:8/16/2017)... 2017  This year,s edition of the Inc. 5000 features a now-familiar ... solutions, has made the list for the third year in a row. ... private companies based on a set of quantitative metrics. In addition, BioPoint ... companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical ... and biotherapeutics development, announces the launch of the new NHS Agile biosensor ... kinetic binding data for a wide range of molecules, including small and large ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):